ATRA - Atara Biotherapeutics, Inc.

4.9
-0.280   -5.714%

Share volume: 34,589
Last Updated: 04-23-2026
Pharmaceutical Products/Biological Products, Except Diagnostic Substances: 0.21%

PREVIOUS CLOSE
CHG
CHG%
$5.18
-0.28
-0.05%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
42%
Profitability 53%
Dept financing 43%
Liquidity 48%
Performance 30%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
-1.80%
1 Month
-1.80%
3 Months
-7.37%
6 Months
-66.18%
1 Year
-35.53%
2 Year
585.60%
Key data
Stock price
$4.90
P/E Ratio 
N/A
DAY RANGE
$4.89 - $5.22
EPS 
$3.14
52 WEEK RANGE
$3.92 - $19.14
52 WEEK CHANGE
-$33.06
MARKET CAP 
0.000
YIELD 
N/A
SHARES OUTSTANDING 
8.178 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
05-08-2025
BETA 
-0.62
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$58,106
AVERAGE 30 VOLUME 
$68,301
Company detail
CEO: Pascal Touchon
Region: US
Website: atarabio.com
Employees: 330
IPO year: 2014
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Biological Products, Except Diagnostic Substances
Sector: Manufacturing

Atara Biotherapeutics, Inc. develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease. The company was incorporated in 2012 and is headquartered in South San Francisco, California.

Recent news